Titan Pharmaceuticals Fully Compliant With NASDAQ Listing Criteria
SOUTH SAN FRANCISCO, Calif., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (“Titan” or the “Company”) today...
Pharmaceutical
Ultragenyx Announces Completion of Dosing Across Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease
Safety and initial efficacy data from Stage 1 expected in the first half of 2024 Dose selection and initiation of...
Travere Therapeutics Announces Licensing Agreement with Renalys Pharma to Develop and Commercialize Sparsentan in Japan, South Korea, Taiwan, and Southeast Asian Nations
Renalys expected to initiate registrational study in the second quarter of 2024 to support potential approval of sparsentan for IgA...
Press Release: Dupixent® FDA approved as first and only treatment indicated for children aged 1 year and older with eosinophilic esophagitis (EoE)
Dupixent® FDA approved as first and only treatment indicated for children aged 1 year and older with eosinophilic esophagitis (EoE) Approval...
Dupixent® (dupilumab) FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and Older with Eosinophilic Esophagitis (EoE)
Approval based on Phase 3 EoE KIDS trial showing a greater proportion of children taking Dupixent achieved histological remission compared...
Scientific Industries Announces Closing of $7.0 Million Private Placement
Proceeds to fund the commercialization of the first multi-parameter sensor for shake flasksBOHEMIA, NY / ACCESSWIRE / January 25, 2024...
Endologix Announces that Art Taylor Joins Board of Directors
IRVINE, Calif.--(BUSINESS WIRE)--Endologix LLC, a privately held, global medical device company dedicated to providing disruptive therapies for the interventional treatment...
Liviniti and Mark Cuban Cost Plus Drug Company Team Up for More Affordable Prescription Drugs
Industry-leading PBM, Liviniti, adds Mark Cuban Cost Plus Drug Company to its network of pharmacy options for membersNatchitoches, Louisiana--(Newsfile Corp....
Dog Study Published in PLOS ONE Shows Statistically Significant Results for Use of Jaguar Health’s Crofelemer for Preventive Treatment of Cancer Therapy-Related Diarrhea (CTD)
This study, conducted by Jaguar family company Napo Pharmaceuticals in collaboration with Puma Biotechnology, is one of three important studies...
SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference
NEW YORK, Jan. 25, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a...
Bright Green Corporation announces the agreement to acquire platform technologies and associated intellectual property from C2 Wellness Corp.
Grants, New Mexico, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Bright Green Corporation (NASDAQ: BGXX) today announced the agreement to purchase...
Windtree Eliminates $15 Million Contingent Liability to Deerfield Management Company
WARRINGTON, Pa., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company...
NightHawk’s Scorpius BioManufacturing Subsidiary Awarded Multimillion- Dollar Contract with a Publicly Traded Biotech Company to Support its Phase 2 Clinical Program
Project to benefit from Scorpius’ comprehensive services in process development, bioanalysis, and cGMP manufacturingDURHAM, N.C., Jan. 25, 2024 (GLOBE NEWSWIRE)...
Processa Pharmaceuticals Announces Successful Completion of Phase 1b Safety Evaluation of NGC-Cap in Patients with Advanced Cancer Resulting in Recommended Phase 2 Doses
Next Generation Capecitabine (NGC-Cap) provides patients with 2-10 times greater exposure to its 5-FU cancer treatment metabolite than capecitabine administration...
Veru to Report Fiscal 2024 First Quarter Financial Results on February 8, 2024
MIAMI, FL, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on...
Reviva Pharmaceuticals to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference
CUPERTINO, Calif., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical...
Ocular Therapeutix™ Announces FDA Agreement to Amend Special Protocol Assessment (SPA) for Pivotal Clinical Trial of AXPAXLI™ in Wet AMD
SPA amendment expands eligibility criteria for SOL clinical trial Broadening of eligibility criteria anticipated to accelerate overall trial enrollment BEDFORD,...
Kronos Bio Implements New Leadership Structure to Drive Pipeline Advancement
Company eliminates three executive officer roles and appoints new Executive Leadership teamSAN MATEO, Calif., and CAMBRIDGE, Mass., Jan. 25, 2024...
eFFECTOR Therapeutics Announces $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Jan. 25, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR) (the “Company”),...
Bionano Announces Publication of a Study that Applied OGM to Discovery of Structural Variants Driving Drug Resistance and Sensitivity in Cancer
SAN DIEGO, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced a peer-reviewed publication in Cancers from...